Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ALB | P02768 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TK1 | P04183 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1902451 | 1.00 | TYMP (0.42) | TYMPALDH1A1LMNAALBPOLB | |
| SCHEMBL12748530 | 1.00 | TYMP (0.42) | TYMPALDH1A1LMNAALBPOLB | |
| SCHEMBL10475695 | 0.91 | TYMP (0.40) | TYMPALDH1A1LMNAALBPOLB | |
| SCHEMBL10474572 | 0.89 | TYMP (0.42) | TYMPALDH1A1LMNAALBPOLB | |
| SCHEMBL10474754 | 0.88 | TYMP (0.41) | TYMPALDH1A1LMNAALBPOLB | |
| SCHEMBL14068557 | 0.87 | TYMP (0.39) | TYMPALDH1A1LMNAALBPOLB | |
| SCHEMBL29367079 | 0.85 | TYMP (0.39) | TYMPALDH1A1LMNAALBPOLB | |
| SCHEMBL13970114 | 0.85 | TYMP (0.41) | TYMPALDH1A1LMNAALBPOLB | |
| SCHEMBL24548479 | 0.83 | TYMP (0.42) | TYMPALDH1A1LMNAALBPOLB | |
| SCHEMBL10474801 | 0.83 | SMN1; SMN2 (0.52) | TYMPALDH1A1LMNAALBPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110195922-A9 | Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B | IDENIX PHARMACEUTICALS, INC. (US) | 2011-08-11 | — | — | US | disclosed |
| US-20100152126-A1 | Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B | IDENIX PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-20080064655-A1 | Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B | INDENIX PHARMACEUTICALS, INC. (US) | 2008-03-13 | — | — | US | disclosed |
| US-20070087995-A1 | beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B | IDENIX PHARMACEUTICALS, INC. (US) | 2007-04-19 | — | — | US | disclosed |
| EP-0898575-B1 | A COMBINATORIAL PROTECTING GROUP STRATEGY FOR MULTIFUNCTIONAL MOLECULES | KOESTER HUBERT DR (US) | 2004-12-29 | — | — | EP | disclosed |
| US-6828435-B2 | Three blocking groups are independently removable under 3 different conditions; using new protection schemes and solid phase synthesis, oligonucleotides are obtained in 5' to 3' direction using phosphoamidites and avoiding depurination | HK PHARMACEUTICALS, INC. | 2004-12-07 | — | — | US | disclosed |
| US-20030194741-A1 | COMBINATORIAL PROTECTING GROUP STRATEGY FOR MULTIFUNCTIONAL MOLECULES | CAPROTEC BIOANALYTICS GMBH (DE) | 2003-10-16 | — | — | US | disclosed |
| US-20030054410-A1 | Combinatorial protecting group strategy for multifunctional molecules | CAPROTEC BIOANALYTICS GMBH (DE) | 2003-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070087995-A1 | beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B | PNP, DUT, ATIC | TYMP 9/4885ALDH1A1 2036/4885LMNA 1188/4885 |
| US-20030194741-A1 | COMBINATORIAL PROTECTING GROUP STRATEGY FOR MULTIFUNCTIONAL MOLECULES | ADAR, RNMT, ATIC | TYMP 144/4885ALDH1A1 4111/4885LMNA 2407/4885 |
| US-20100152126-A1 | Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B | PNP, DUT, ATIC | TYMP 9/4885ALDH1A1 2036/4885LMNA 1188/4885 |
| US-20030054410-A1 | Combinatorial protecting group strategy for multifunctional molecules | ADAR, RNMT, RRM1 | TYMP 99/4885ALDH1A1 3683/4885LMNA 2581/4885 |
| US-20080064655-A1 | Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B | ATIC, SLC35B2, AASDHPPT | TYMP 34/4885ALDH1A1 2228/4885LMNA 795/4885 |
| US-20110195922-A9 | Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B | PNP, DUT, ATIC | TYMP 9/4885ALDH1A1 2036/4885LMNA 1188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.